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The encapsulation of Ib-M6 antibacterial peptide in pellets of polyvinyl alcohol (PVA) and polyvinyl alcohol-
alginate (PVA-Alg) matrices was carried out in order to explore its controlled release and activity against
Escherichia coli K-12. The pellets were obtained by combined ice segregation induced self-assembly (ISISA) and
freezing-thawing methods and their microstructure was studied by scanning electron microscopy. Bromothymol
blue was used as a model compound to study the transport mechanisms and release from pellets. The results show
that there is a significant effect of the total concentration of PVA precursor solutions, the mass ratio of PVA of
different molecular weights and the addition of alginate on the microstructure and transport properties of pellets.
The antibacterial activity of Ib-M6 against Escherichia coli K-12 was not affected by the encapsulation in PVA
pellets. However, the release of Ib-M6 from PVA-Alg pellets was not possible, probably due to the electrostatic
interaction of positively charged Ib-M6 and negatively alginate structure. Nonetheless, the controlled release of
Ib-M6 from polymeric matrices can be fitting by modifying parameters such as the concentration and type of
polymer precursors.1. Introduction
Antibacterial resistance is one of the biggest challenges in public
health worldwide which has generated the need to develop new more
efficient antibacterial compounds [1]. In this sense, antimicrobial pep-
tides (AMPs) arise as an alternative to treatment with conventional an-
tibiotics because they have a broad spectrum of action. AMPs exhibit
antibacterial activity against gram-negative and gram-positive bacteria,
as well as antifungal and antiviral activity [2, 3, 4]. Also, AMPs have low
toxicity against human cells and they exhibit different mechanisms of
action, which hinders the generation of bacterial resistance [5, 6].
Recently, it was reported an analog of Ib-AMP4 antimicrobial peptide
named Ib-M6 (sequence EWGRRMMGWGRGRRMMRRWW-NH2). This
peptide is characterized by having a high positive charge (þ6) due to R
residues and high hydrophobicity by W residues. This leads to exhibit
antibacterial activity against Escherichia coli K-12 with IC50 of 1 μM. Also,
Ib-M6 did not exhibit hemolytic activity at this concentration [7]..M. Florez-Castillo), jose.ropero@
rm 21 May 2019; Accepted 29 M
vier Ltd. This is an open access arAlthough AMPs have an important activity in vitro, their properties
exhibit a significant decrease in vivo due to factors such as degradation by
proteases and the dependence of the concentration of salts in the serum,
which hinders its formulation [8]. For this reason, various controlled
release systems have been designed to reduce the degradation of AMPs
and allow them to keep their activity in the concentration of the thera-
peutic range [9, 10, 11].
Polymeric matrices have attracted great interest as new systems in the
development of controlled release of biologically active molecules due to
their versatility, biocompatibility and biodegradability [12]. Pellets are
commonly used for this purpose due to the decrease in the exposure time
of biomolecules in the gastrointestinal tract and they can be prepared
from different polymers [13].
Polyvinyl alcohol (PVA) is a synthetic polymer with protein structure
stabilization properties and preservation of the biological activity [14]. It
is possible to obtain PVA pellets through different procedures such as ice
segregation induced self-assembly (ISISA), in which unidirectionaludes.edu.co (J.L. Ropero-Vega).
ay 2019
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[15]. This method allows obtaining microchannels in the pellet by the
formation of ice crystals in the freezing direction of PVA aqueous pre-
cursor solutions [16]. The type of obtained pore will depend on variables
such as impurities in precursor solutions, the total concentration and the
degree of hydrolysis of PVA [16]. Furthermore, we previously reported
for the first time, to our knowledge, the structure and stability of PVA
polymeric matrices are significantly affected by the molecular weight of
PVA used as precursors [17].
Another commonly used method is freezing-thawing process which
consists of physical cross-linking of PVA for obtaining hydrogels with
high elasticity and stability [18]. However, obtaining PVA pellets is
difficult due to the presence of hydroxyl groups that give hydrophilic
characteristics to the polymer, allowing to trap large amounts of water
inside its structure, which decreases its stability [19].
Sodium alginate (Alg) is a natural polymer widely used in biomedical
applications. This polymer has been used for the encapsulation of bio-
molecules as insulin [20, 21, 22] and glucose oxidase [23, 24] and it
consists of units of β-D-mannuronic acid and α-L-glucuronic acid with a
pKa between 3.38 and 3.65 [25]. This allows controlling its charge at
different pH values making it a system of great interest for oral controlled
release drug delivery. Sodium alginate form hydrogels with small pores
up to 200 nm by ionotropic gelation using divalent ions such as Ca2þ
[26]. Despite the above, calcium alginate pellets exhibit low retention
capacity of encapsulated molecules [27, 28].
Keeping in mind the above, in this work we report the encapsulation
of Ib-M6 peptide in PVA and PVA-Alg pellets. The antibacterial activity of
Ib-M6 released from pellets was evaluated against Escherichia coli K-12
used as gram-negative reference bacteria. This constitutes the continua-
tion of exploratory work to determine the spectrum of activity of the Ib-
M6 peptide and its potential use in biological systems.
2. Materials and methods
2.1. Materials
The following reagents were used as received without further puri-
fication: Polyvinyl alcohol (PVA23, Aldrich, Mw 13000–23000, 98%
hydrolysed), polyvinyl alcohol (PVA98, Aldrich, Mw 89000–98000,
99þ% hydrolysed), alginic acid sodium salt (Panreac, Mw
10000–600000), calcium chloride dihydrate (ACS reagent), bromothy-
mol blue (Aldrich, 95%, ACS reagent), Müller-Hinton broth (MHB,
Scharlau), sodium chloride (USP, Panreac) and deionized water (18 MΩ
cm at 25 C). Ib-M6 (sequence EWGRRMMGWGRGRRMMRRWW-NH2)
antibacterial peptide was supplied by Biomatik.
2.2. Preparation of PVA and PVA-Alg pellets
PVA pellets were prepared using an ISISA modified procedure pub-
lished previously [17]. Briefly, three aqueous solutions of precursor
polymers with a total concentration of PVA (PVA23þ PVA98) of 2.5, 5.0
and 7.5% (w/v) were prepared, respectively. The PVA23:PVA98 mass
ratio was 1:3 in all cases. The solutions of precursor polymers were
dropped into liquid nitrogen using a syringe needle (0.8 mm  40 mm).
Subsequently, the obtained pellets were lyophilized using an Alpha 1–2
LD Plus freeze-drier. The nomenclature assigned to each obtained pellet
is shown in Table 1.Table 1
Nomenclature assigned to each PVA pellet.




* PVA23 þ PVA98.
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PVA-Alg pellets were prepared by ionotropic gelation of alginate
followed by a physical cross-linking of PVA precursors by freeze-thaw
method [29]. In this case, aqueous solutions of precursor polymers
containing simultaneously dissolved PVA23, PVA98 and alginic acid
sodium salt were used. The total concentration of PVA was fixed at 5.0%
(w/v) (defined by preliminary results of PVA pellets) and alginic acid
sodium salt was varied in the range of 0.5–1.5% (w/v). The solutions of
precursor polymers were dropped into a CaCl2 1.5M aqueous solution
(pH adjusted to 5.6) using a syringe needle (0.8 mm  40 mm) under
continuous magnetic stirring (500 rpm) at 25 C. The stirring was
maintained for 1 h and the obtained pellets were filtered and washed
with deionized water. These pellets were frozen at -20 C for 12h and
thawed at 25 C for 4h. Finally, the pellets were stored at 4 C. The
nomenclature of pellets and the conditions of preparation are shown in
Table 2.
2.3. Encapsulation in PVA and PVA-Alg pellets
Bromothymol blue (BB) was used as a model compound to evaluate
the transport properties of pellets. This compound was chosen because it
is possible to modify the charge thereof by varying the pH of the medium
due to its pKa (7.1), either encapsulation or release. For the encapsula-
tion, a stock solution of BB was added to the aqueous solution of pre-
cursor polymers of PVA and PVA-Alg in such of a way that the final
concentration of BB was 89.5 mg/L in all cases.
The experiments of controlled release of BB were carried out in water
at pH 7.4 (adjusted with NaOH). For this, three pellets of each prepara-
tion were added in separate vessels containing 2.0 mL of water under
permanent stirring in a shaker (250 rpm) at 25 C. The release of BB was
monitored by measuring the absorbance at 620 nm using an AvaSpec-
2048 fiber optic spectrometer (Avantes).
Ib-M6 antimicrobial peptide was encapsulated in PVA and PVA-Alg
pellets following the same procedure used for the encapsulation of BB.
In this case, the concentration of Ib-M6 in the aqueous solutions of pre-
cursor polymers was 100 μM.
2.4. PVA and PVA-Alg pellets characterization
Scanning electron micrographs of PVA and PVA-Alg pellets were
obtained with a Quanta Field Emission Gun microscope (model 650)
operated at 20.0 kV. The images were obtained in the secondary electron
mode. In all cases, pellets were sputtered with Au (60 s) prior to analyses
in order to prevent electric charging.
Fourier-transform infrared (FTIR) measurements of PVA-Alg pellets
were performed using a Bruker Tensor II spectrometer equipped with a
Platinum ATR cell and a cooled deuterated triglycine sulfate (DTGS)
detector. The ATR-FTIR spectra were collected with 16 scans at a reso-
lution of 5 cm1.
2.5. Antibacterial activity against E. coli
The activity of the Ib-M6 released from biopolymeric pellets was
evaluated against Escherichia coli K-12 by the plate count technique. For
this, E. coli K-12 was cultured aerobically in Müller-Hinton Broth (MHB)Table 2
Composition of PVA-Alg pellets. These conditions were established in the anal-
ysis of PVA pellets.
Total concentration of
polymers (%w/v)*







* PVA23 þ PVA98 þ alginic acid sodium salt.
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solution to achieve an inoculum of approximately 1108 colony forming
units per mL (CFU/mL). Aliquots of 250 μL were added to well of 96-well
plate and one pellet of each preparation was used. The growth kinetics of
E. coli were determined for 6 h. For this, ten-fold serial dilutions were
made of the inoculum of the bacteria and 3 μL of each dilution were
seeded in petri dish. Finally, the count of colony forming units (CFU) was
made. Negative and positive growth controls were performed by adding
only E. coli, pellets without peptide and free Ib-M6 peptide in Tris buffer
(10 mM, pH 7.4) at a concentration of 5 μM.
3. Results and discussion
3.1. Structural characterization of pellets
The effect of varying the total concentration of PVA from 2.5 to 7.5%
(w/v) on the microstructural properties was evaluated. Scanning electron
micrographs (SEM) of PVA pellets are shown in Fig. 1. The obtained
pellets have an average diameter from 2.24 to 2.58 mm (Fig. 1a,d,g).
The morphology and microstructure of pellets are amorphous when a
total concentration of PVA of 2.5% (w/v) was used (Fig. 1a-c). This is due
to the low amount of polymer produces a more unstable structure that
collapses when ice crystals are removed. On the other hand, compact
structures with defined channels and aligned in the cooling direction
were observed when the total concentration of PVA increases to 5.0 or
7.5% (w/v) (Fig. 1d-i). The polymer concentration defines the amount of
ice crystals formed in the freezing process and that are removed by
lyophilization process.
Considering the above, PVA concentration of 5.0% (w/v) was
selected to prepare PVA-Alg pellets. These pellets were obtained by
ionotropic gelation of alginate followed by physical cross-linking of PVA
by freeze-thaw method. In all cases, the PVA concentration was keptFig. 1. Scanning electron micrographs of PV25 (a,
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constant while alginate was varied from 0.5 to 1.5% (w/v) (see Table 2).
The microstructure of PVA-Alg pellets was analyzed by SEM and the
results are shown in Fig. 2.
The obtained pellets have a mean diameter between 1.39 and 1.53
mm. The results show that the structure of pellets prepared with relative
low alginate concentration (0.5 and 1.0%) collapse after physical cross-
linking processes. Furthermore, they exhibit amorphous and disordered
channels (Fig. 2a-d). Nevertheless, it was observed that the morphology
is more defined when the total polymer concentration increases (Fig. 2e).
Fourier-transform infrared spectroscopy (FTIR) was used in order to
evaluate the interaction between the polymers present in the structure
(Fig. 3).
The OH stretching vibrations of PVA23, PVA98 and NaAlg are
observed between 3285 and 3245 cm1 (Fig. 3a-c). This band appears in
3365 cm1 for pellets (Fig. 3d-f). The band around 1520 cm1 in Fig. 3c is
assigned to the carbonyl group of NaAlg while band around 1662 cm1 of
PVA23 (Fig. 3a) is due to the stretching of C¼O and C–O groups from the
unhydrolyzed part in the polymer. This band is absent in Fig. 3b because
PVA98 is 99% hydrolyzed. Meanwhile, the stretching C¼O of NaAlg in
pellets appears in 1642 cm1.
3.2. Release of BB from PVA and PVA-Alg pellets
Bromothymol blue (BB) was used as a model compound in order to
evaluate the encapsulation-release processes of positively charged mol-
ecules in PVA and PVA-Alg pellets. The release kinetic curve of BB from
PVA pellets is shown in Fig. 4.
The increase in the total concentration of PVA favors a fast release of
BB. It was previously reported [17] that PV75 pellets experiment a
swelling of their structure when they come into contact with water. This
is favored by their well-consolidated microstructure and channels. This
phenomenon allows the fast release of BB by simple diffusion. On theb, c), PV50 (d, e, f) and PV75 (g, h, i) pellets.
Fig. 2. SEM micrographs of PVA-Alg pellets: (a, b) PV50-A05 (c, d) PV50-A10 and (e, f) PV50-A15.
Fig. 3. FTIR spectra of precursor polymers (top) and PVA-Alg pellets (bottom):
(a) PVA23 precursor, (b) PVA98 precursor, (c) alginic acid sodium salt precursor
and pellets of (d) PV50-A05, (e) PV50-A10 and (f) PV50-A15.
Fig. 4. Bromothymol blue release from PV25 (■), PV50 (●) and PV75
(▴) pellets.
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other hand, PV25 and PV50 pellets do not exhibit a significant difference
in kinetic behavior probably due to the release of BB is by an erosion
mechanism [17].
The release kinetics of BB from PVA pellets was evaluated using the
mathematical model proposed by Korsmeyer-Peppas [30]. The release
curves can be parameterized by the following general expression (Eq. 1),
which describes the solute release from hydrophilic polymers.
Mt =M∞ ¼ ktn (1)
Where Mt/M∞ is the fractional BB released at time t, k is a kinetic con-
stant and n is the diffusional exponent which is related to release
mechanisms [31, 32, 33]. The obtained parameters for each curve in
Fig. 4 are reported in Table 3. It was not possible to perform the analysis
for PV75 because these pellets release more than 60% of BB before 2 min.
Considering the correlation coefficient, the adjustment of the ob-
tained results with the proposed model was not satisfactory. This in-
dicates the presence of complex release mechanisms as dye diffusion and
Table 3
Kinetic obtained parameters for each PVA pellet according to Korsmeyer-Peppas
model.
Pellet k n R2
PV25 0.2190 0.2900 0.94353
PV50 0.2561 0.3102 0.97491
PV75 N.C. N.C. N.C.
N.C. Not calculated. k is the kinetic constant. n is the diffusional exponent. R is
the correlation coefficient.
Table 4
Resulting kinetic obtained parameters for each PVA-Alg pellet.
Pellet k n R2
PV50-A05 0.04500 0.4462 0.95428
PV50-A10 0.07453 0.4288 0.94268
PV50-A15 0.03450 0.4471 0.94098
k is the kinetic constant. n is the diffusional exponent. R is the correlation
coefficient.
Fig. 6. Growth kinetics of E. coli K-12 in the absence (●) and presence of free
(▴) and encapsulated Ib-M6 peptide on PV50 pellets (▾). Results of E. coli K-12
in presence of PV50 (■) pellets without the addition of Ib-M6 were included for
comparative purposes.
J.M. Florez-Castillo et al. Heliyon 5 (2019) e01872swelling, dissolution or erosion of pellets [32]. In spite of the above, it
was observed an effect of the total concentration of PVA on the release
kinetics of BB. As mentioned above, the microstructure of PV75 pellets
favors swelling thereof which results in a fast and uncontrolled release of
the dye. On the other hand, the PV25 and PV50 pellets exhibit a gradual
release, but the latter has a well-consolidated microstructure. Taking into
account the above, the PV50 pellets were selected to be modified with
alginate in order to improve the release characteristics.
The release kinetic curve of BB from PVA-Alg pellets is shown in
Fig. 5. The results show a considerable control in the dye release when
alginate is used. However, the amount of BB released does not reach the
amount released by PV50 pellets at the time evaluated. It can be observed
that the release kinetic increases when the alginate concentration in-
creases from 0.5 to 1.0%. However, a significant decrease in the release
rate of BB is observed at an alginate concentration of 1.5%. This can be
due to the fact that the structure of the PV50-A15 pellets is compact,
which limits the transport of the dye.
Resulting parameters from the fitting of each curve according to
Korsmeyer-Peppas model are shown in Table 4.
As in PVA pellets results, the kinetic model used for PVA-Alg system
does not fit to the obtained results and the release mechanisms are
complex. Nevertheless, diffusional exponent n > 0.43 indicates a non-
Fickian transport mechanism which is consistent with what is reported
in the literature for PVA systems [32].
The above results show that the release mechanism of BB from PVA-
Alg pellets can be governed by two processes, considering that this dye
has a negative charge on the pH of the release medium. First, the charge
repulsion between the negatively charged polymer (alginate) and BB
causes the last one to be expelled towards outside. Second, the micro-
structure compaction as a result of the increase in the total alginate
concentration will limit the diffusion of molecules from the inside of the
sphere to the outside. This allows performing fine control of release ki-
netics by modifying the microstructural (pore size) and charge (by the
addition of negatively charged polymers) properties of pellets.Fig. 5. Bromothymol blue release from PV50-A05 (■), PV50-A10 (●) and
PV50-A15 (▴) pellets. The result of PV50 pellets (◆) was included for
comparative purposes.
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3.3. Antibacterial activity of Ib-M6 peptide released from biopolymeric
pellets
E. coli K-12 was used as a reference bacterium in order to evaluate the
activity of the Ib-M6 peptide when it is released from pellets. The growth
kinetics of E. coli K-12 in the presence and absence of free and encap-
sulated Ib-M6 peptide on biopolymeric pellets are shown in Fig. 6. The
concentration used for free peptide was 5.0 μM.
It was not observed growth of microorganisms in the presence of Ib-
M6 peptide both free and encapsulated in PV50 pellets. This indicates
that the activity of this peptide is not affected by the encapsulation in
polyvinyl alcohol matrices. Also, it is noteworthy that there is no sig-
nificant difference in the activity of the peptide when it is encapsulated.
On the other hand, it was found that there is no masking effect on the
activity of the peptide by the presence of PVA, since no effect on the
growth of E. coli was observed. This can be seen in Fig. 6 where it is
shown that the growth kinetics of E. coli in the presence of PV50 pellets is
similar to the bacteria alone. This is because PVA is a non-toxic and
biocompatible polymer that it does not have an effect on the bacteria.
Contrary to expectations, it was not possible to carry out the Ib-M6
peptide release from PVA-Alg system. This can be due to the highly
positively charged peptide molecules (6þ) that are trapped on the
negatively charged alginate network which prevent their release.
4. Conclusions
The ISISAmethodwas useful to control the structure of PVA pellets by
modifying the total concentration of PVA in the precursor solution.
Amorphous pellets with poorly defined channels were obtained at a total
concentration of PVA of 2.5% (w/v), while structures with radially
aligned microchannels were obtained at 7.5% (w/v). Moreover, the
addition of alginate to the PVA pellets favours the structure compaction.
Variations in the total concentration of PVA, mass ratio of PVA and
J.M. Florez-Castillo et al. Heliyon 5 (2019) e01872alginate addition allowed to modify the release rate of bromothymol blue
(used as reference) for a time of 60 min. However, it was not possible
fitting the dye release kinetics to the model proposed by Korsmeyer-
Peppas. The above indicates that it is possible that non-Fickian pro-
cesses govern the transport mechanisms.
The encapsulation of Ib-M6 peptide in PVA pellets did not affect the
antimicrobial activity against Escherichia coli. In addition, polymer
masking effect on antimicrobial activity was not observed. Finally, it was
not possible to achieve Ib-M6 release from the PVA-Alg pellets probably
due to electrostatic attraction between the high positive charge of the
peptide and the negative charge of the alginate.
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